Verona Pharma Plc Stock London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
|
Sales 2024 * | 4.75M 6.18M | Sales 2025 * | 66.09M 85.95M | Capitalization | 1.42B 1.85B |
---|---|---|---|---|---|
Net income 2024 * | -104M -135M | Net income 2025 * | -84M -109M | EV / Sales 2024 * | 300 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 21.5 x |
P/E ratio 2024 * |
-24.9
x | P/E ratio 2025 * |
-40.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma Plc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 117B | |
+23.26% | 27.52B | |
-18.07% | 20.87B | |
-15.13% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |